Inhibitor timidilatne sintaze
Inhibitori Timidilatne sintaze su hemijski agensi koji inhibiraju enzim timidilatna sintaza, te mogu da nađu primenu u antikancernoj hemoterapiji[1]. Pet agenasa je bilo u kliničkim israživanje 2002: raltitreksed, pemetreksed, nolatreksed, ZD9331, i GS7904L.[2]
Primeri lekova ove klase su:
- Raltitreksed, koristi se za kolorektalni kancer od 1998
- Fluorouracil, koristi se za kolorektalni kancer[3]
- BGC 945[4]
- OSI-7904L[5]
Reference[uredi | uredi izvor]
- ^ Jackman, A.L.; Calvert, A.H. (1995). „Folate-based thymidylate synthase inhibitors as anticancer drugs”. Annals of Oncology. 6 (9): 871—881.
- ^ „Thymidylate synthase inhibitors as anticancer agents: from bench to bedside”. Pristupljeno 28. 1. 2009.
- ^ Papamichael, D. (1999). „The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status”. Oncologist. 4 (6): 478—87. PMID 10631692.
- ^ Gibbs, David D.; et al. (2005). „BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to α-folate receptor-overexpressing tumors”. Cancer Research. 65 (24): 11721—11728. doi:10.1158/0008-5472.CAN-05-2034.
- ^ Ricart, AD; Berlin, JD; Papadopoulos, KP; et al. (decembar 2008). „Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors”. Clin. Cancer Res. 14 (23): 7947—55. PMID 19047127. doi:10.1158/1078-0432.CCR-08-0864.